Zacks: G1 THERAPEUTICS (NASDAQ:GTHX) Given $29.33 Average Price Target by Brokerages
Shares of G1 THERAPEUTICS (NASDAQ:GTHX) have received an average broker rating score of 1.25 (Strong Buy) from the four brokers that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a buy recommendation and three have assigned a strong buy recommendation to the company.
Analysts have set a twelve-month consensus price objective of $29.33 for the company and are predicting that the company will post ($0.63) earnings per share for the current quarter, according to Zacks. Zacks has also given G1 THERAPEUTICS an industry rank of 108 out of 265 based on the ratings given to its competitors.
Several research firms have weighed in on GTHX. Cowen and Company began coverage on G1 THERAPEUTICS in a research note on Monday, June 12th. They set an “outperform” rating and a $31.00 target price for the company. Wedbush began coverage on G1 THERAPEUTICS in a research note on Monday, June 12th. They set an “outperform” rating and a $31.00 target price for the company. Needham & Company LLC began coverage on G1 THERAPEUTICS in a research note on Monday, June 12th. They set a “buy” rating and a $34.00 target price for the company. Finally, J P Morgan Chase & Co began coverage on G1 THERAPEUTICS in a research note on Monday, June 12th. They set an “overweight” rating and a $23.00 target price for the company.
COPYRIGHT VIOLATION NOTICE: “Zacks: G1 THERAPEUTICS (NASDAQ:GTHX) Given $29.33 Average Price Target by Brokerages” was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/08/07/zacks-g1-therapeutics-nasdaqgthx-given-29-33-average-price-target-by-brokerages.html.
In related news, Director Fredric N. Eshelman purchased 300,000 shares of the stock in a transaction dated Monday, May 22nd. The stock was bought at an average cost of $15.00 per share, for a total transaction of $4,500,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Ra Capital Healthcare Fund Lp purchased 400,000 shares of the stock in a transaction dated Monday, May 22nd. The shares were bought at an average price of $15.00 per share, with a total value of $6,000,000.00. The disclosure for this purchase can be found here. Insiders have acquired 833,333 shares of company stock valued at $12,499,995 over the last 90 days.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Alps Advisors Inc. bought a new position in shares of G1 THERAPEUTICS during the second quarter valued at about $444,000. Victory Capital Management Inc. bought a new position in shares of G1 THERAPEUTICS during the second quarter valued at about $889,000. Finally, Chartwell Investment Partners LLC bought a new position in shares of G1 THERAPEUTICS during the second quarter valued at about $1,538,000. Institutional investors own 4.57% of the company’s stock.
G1 THERAPEUTICS (NASDAQ:GTHX) traded up 1.14% during midday trading on Wednesday, reaching $13.27. The company had a trading volume of 69,295 shares. The firm has a 50-day moving average of $16.23 and a 200-day moving average of $16.69. The stock’s market cap is $19.64 million. G1 THERAPEUTICS has a 12 month low of $12.41 and a 12 month high of $20.60.
G1 THERAPEUTICS Company Profile
G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for G1 THERAPEUTICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 THERAPEUTICS and related companies with MarketBeat.com's FREE daily email newsletter.